Initial clinical experience with clinafloxacin in the treatment of serious infections.
Tack
K J
KJ
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA.
McGuire
N M
NM
Eiseman
I A
IA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002939:Ciprofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D002939:Ciprofloxacin; C057477:clinafloxacin